


Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. (Currently Amended) A compound represented by the formula (I):



wherein R represents an optionally substituted cyclic hydrocarbon group or an optionally substituted heterocyclic group is naphthyl optionally substituted with a halogen atom or indolyl optionally substituted with a halogen atom, W represents a bond or an optionally substituted divalent linear hydrocarbon group, X represents an optionally substituted divalent hydrocarbon group, Y represents -CO-, -S(O)-, -S(O)₂- or a bond, ring A represents an optionally substituted pyrrolidine ring, an optionally substituted piperidine ring or an optionally substituted perhydroazepine ring, Z¹ and Z³ independently represent a bond or an optionally substituted divalent linear hydrocarbon group, Z² represents -N(R¹)-, -O-, -S(O)-, -S(O)₂-, -CO-, -CH(R¹)- or a bond (R¹ represents a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted acyl group, an optionally esterified carboxyl group or an optionally substituted carbamoyl group), ring B represents an optionally substituted imidazole ring, wherein a substituent which that the optionally substituted imidazole ring represented by ring B may have ~~may be taken~~ together with R¹ to form an optionally substituted ring, and a represents 0, 1 or 2, or a salt thereof.

2. (Cancelled)
 3. (Cancelled)

4. (Cancelled)

5. (Original) The compound according to claim 1, wherein W is a bond.

6. (Original) The compound according to claim 1, wherein X is an optionally substituted divalent linear hydrocarbon group.


7. (Cancelled)

8. (Cancelled)

9. (Original) The compound according to claim 1, wherein the formula:



is the formula:




wherein R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^8 , R^9 , R^{10} , R^{11} , R^{12} and R^{13} independently represent a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted hydroxyl group, an optionally substituted thiol group, an optionally substituted alkylsulfinyl group, an optionally substituted alkylsulfonyl group, an optionally substituted acyl group, an optionally esterified carboxyl group, an optionally substituted carbamoyl group or an optionally substituted amino group, or R^2 and R^3 , R^5 and R^6 , R^6 and R^7 , R^8 and R^9 , R^9 and R^{10} , or R^{11} and R^{12} may be taken together to form an optionally substituted ring.

10. (Original) The compound according to claim 1, wherein the formula:



is the formula:




wherein ring C represents an optionally substituted nitrogen-containing heterocyclic ring, and other symbols are as defined in claim 9.

11. (Currently Amended) The compound according to claim 1, wherein a substituent which that the optionally substituted imidazole ring represented by ring B may have and R¹ together do not form a ring.

12. (Cancelled)

13. (Currently Amended) The compound according to claim 1, wherein the formula (I) is the formula (Ia):




wherein ring B' represents an optionally further substituted imidazole ring, Z^{2a} represents N- or -CH, Z⁴ represents an optionally substituted divalent linear hydrocarbon group, and other symbols are as defined in claim 1.

14. (Cancelled)


15. (Original) The compound according to claim 13, wherein Z^3 and Z^4 are independently a divalent linear hydrocarbon group optionally substituted with an oxo group.

16. (Original) The compound according to claim 1, wherein the formula (I) is the formula (Ib):



wherein R^{14} and R^{15} independently represent a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted hydroxyl group, an optionally substituted thiol group, an optionally substituted alkylsulfinyl group, an optionally substituted alkylsulfonyl group, an optionally substituted acyl group, an optionally esterified carboxyl group, an optionally substituted carbamoyl group, or an optionally substituted amino group, or R^{14} and R^{15} may be taken together to form an optionally substituted ring, and other symbols are as defined in claim 1 or 13.


17. (Original) The compound according to claim 1, wherein the formula (I) is the formula (Ic):



wherein R^{16} and R^{17} independently represent a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted hydroxyl group, an optionally substituted thiol group, an optionally substituted alkylsulfinyl group, an optionally substituted alkylsulfonyl group, an optionally substituted acyl group, an optionally esterified carboxyl group, an optionally substituted carbamoyl group or an optionally substituted amino group,

or R¹⁶ and R¹⁷ may be taken together to form an optionally substituted ring, and other symbols are as defined in claim 1 or 13.

18. (Original) The compound according to claim 1, wherein the formula (I) is the formula (Id):



wherein R¹⁸ and R¹⁹ independently represent a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted hydroxyl group, an optionally substituted thiol group, an optionally substituted alkylsulfinyl group, an optionally substituted alkylsulfonyl group, an optionally substituted acyl group, an optionally esterified carboxyl group, an optionally substituted carbamoyl group, or an optionally substituted amino group, and other symbols are as defined in claim 1 or 13.

19. (Cancelled)

20. (Currently Amended) A compound selected from the group consisting of
 7-(1-{3-[(6-chloro-2-naphthyl)sulfonyl]propanoyl}-4-piperidinyl)-3-methyl-6,7-dihydroimidazo[1,5-a]pyrazin-8(5H)-one,
 7-(1-{3-[(6-chloro-2-naphthyl)sulfonyl]propanoyl}-4-piperidinyl)-1-methyl-6,7-dihydroimidazo[1,5-a]pyrazin-8(5H)-one,
 2-(1-{3-[(6-chloro-2-naphthyl)sulfonyl]propanoyl}-4-piperidinyl)-5-methyl-1,2-dihydro-3H-imidazo[1,5-c]imidazol-3-one,
 2-(1-{3-[(6-chloro-2-naphthyl)sulfonyl]propanoyl}-4-piperidinyl)-5,7-dimethyl-1,2-dihydro-3H-imidazo[1,5-c]imidazol-3-one,

2-(1-{3-[(7-chloro-2H-chromen-3-yl)sulfonyl]propanoyl}-4-piperidinyl)-5-methyl-1,2-dihydro-3H-imidazo[1,5-c]imidazol-3-one,
2-[1-(3-[(E)-2-(4-chlorophenyl)vinyl]sulfonyl]propanoyl)-4-piperidinyl]-5-methyl-1,2-dihydro-3H-imidazo[1,5-c]imidazol-3-one,
2-(1-{3-[(5-chloro-1H-indol-2-yl)sulfonyl]propanoyl}-4-piperidinyl)-5-methyl-1,2-dihydro-3H-imidazo[1,5-c]imidazol-3-one,
2-(1-{3-[(6-chloro-2-naphthyl)sulfonyl]propanoyl}-4-piperidinyl)-5-(hydroxymethyl)-1,2-dihydro-3H-imidazo[1,5-c]imidazol-3-one,
2-(1-{(2S)-3-[(6-chloro-2-naphthyl)sulfonyl]-2-hydroxypropanoyl}-4-piperidinyl)-5-(hydroxymethyl)-1,2-dihydro-3H-imidazo[1,5-c]imidazol-3-one,
[2-(1-{(2S)-3-[(6-chloro-2-naphthyl)sulfonyl]-2-hydroxypropanoyl}-4-piperidinyl)-3-oxo-2,3-dihydro-1H-imidazo[1,5-c]imidazol-5-yl]methyl 1-acetyl piperidine-4-carboxylate,
[2-(1-{(2S)-3-[(6-chloro-2-naphthyl)sulfonyl]-2-hydroxypropanoyl}-4-piperidinyl)-3-oxo-2,3-dihydro-1H-imidazo[1,5-c]imidazol-5-yl]methyl 3-(2-oxo-1-pyrrolidinyl)propionate,
[2-(1-{(2S)-3-[(6-chloro-2-naphthyl)sulfonyl]-2-hydroxypropanoyl}-4-piperidinyl)-3-oxo-2,3-dihydro-1H-imidazo[1,5-c]imidazol-5-yl]methyl (2-oxo-1-pyrrolidinyl)acetate,
[2-(1-{(2S)-3-[(6-chloro-2-naphthyl)sulfonyl]-2-hydroxypropanoyl}-4-piperidinyl)-3-oxo-2,3-dihydro-1H-imidazo[1,5-c]imidazol-5-yl]methyl 4-(acetylamino)butanoate, and
2-(1-{(2S)-3-[(6-chloro-2-naphthyl)sulfonyl]-2-hydroxypropanoyl}-4-piperidinyl)-5,7-dimethyl-1,2-dihydro-3H-imidazo[1,5-c]imidazol-3-one or a salt thereof.

21. (Previously Presented) A pharmaceutical preparation which comprises the compound according to claim 1.

22. (Currently Amended) The pharmaceutical preparation according to claim 21, which is has an anticoagulant effect.

23. (Currently Amended) The pharmaceutical preparation according to claim 21, which is inhibits an activated blood coagulation factor X-inhibitor.

24. (Currently Amended) The pharmaceutical preparation[[n]] according to claim 21, which is ~~an agent for~~ has an effect on preventing or treating myocardial infarction, cerebral infarction, deep venous thrombosis, pulmonary thromboembolism or arteriosclerotic obliterans.

25. (Currently Amended) The pharmaceutical preparation according to claim 21, which is ~~an agent effective for~~ has an effect on preventing or treating economy class syndrome, thromboembolism during or after an operation, or a secondary onset of deep venous thrombosis.

26 - 37. (Cancelled)